HSBC Holdings
LYEL icon

HSBC Holdings’s Lyell Immunopharma LYEL Stock Holding History

HSBC Holdings’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-936
Closed -$9.67K – 3150
2025
Q1 		$9.67K Sell
936
-6
-0.6% -$74 ﹤0.01% 2986
2024
Q4 		$11.9K Buy
942
+361
+62% +$7.16K ﹤0.01% 3066
2024
Q3 		$16.3K Sell
581
-335
-37% -$9.84K ﹤0.01% 2952
2024
Q2 		$25.3K Buy
916
+20
+2% +$952 ﹤0.01% 2863
2024
Q1 		$40K Buy
+896
New +$38.4K ﹤0.01% 2952

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HSBC Holdings's LYEL Position: Q2 2025 in Review

HSBC Holdings sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 936 shares — an estimated $9.67K sold.

HSBC Holdings first reported a position in LYEL in Q1 2024 and held it in 5 quarters. The position peaked at $40K in Q1 2024. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • HSBC Holdings reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • HSBC Holdings sold 936 Lyell Immunopharma shares in Q2 2025, an estimated $9.67K.
  • HSBC Holdings first reported a position in Lyell Immunopharma in Q1 2024 and held it in 5 quarters.
  • HSBC Holdings's Lyell Immunopharma position peaked at $40K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.